An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
Public ClinicalTrials.gov record NCT00051779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-Week Blinded Study Conducted at Multiple Centers, Evaluating the Safety and Effectiveness of Various Doses of the Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) When Randomly Assigned to Patients With Breast Cancer That Has Metastasized to Bone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid in patients with breast cancer metastatic to bone. The study will also evaluate the possible effects of both study drugs on performance status, markers of bone metabolism, and skeletal events related to bone metastasis including elevated blood calcium levels, bone pain, metastatic lesions, complications and interventions. The levels of CAL in the blood will also be evaluated.
Study identification
- NCT ID
- NCT00051779
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 24, 2005
United States locations
- U.S. sites
- 38
- U.S. states
- 23
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72764 | — |
| Bay Area Cancer Research Group | Concord | California | 94520 | — |
| California Cancer Care, Inc. | Greenbrae | California | 94904 | — |
| Institute of Cancer Therapies | Los Angeles | California | — | — |
| San Diego Cancer Research Institute | Vista | California | 92083 | — |
| Anschutz Cancer Pavilion at the University of Colorado Cancer Center | Aurora | Colorado | 80010-0510 | — |
| Yale University | New Haven | Connecticut | 06520-8028 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Rush Cancer Institute | Chicago | Illinois | 60612-3824 | — |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536-0098 | — |
| Louisiana State University | New Orleans | Louisiana | 70112-2278 | — |
| Frederick Memorial Hospital | Frederick | Maryland | 21701 | — |
| Dana-Farber/Harvard Cancer Center | Boston | Massachusetts | 02115 | — |
| Josephine Ford Cancer Center | Detroit | Michigan | 48202 | — |
| Spectrum Health | Grand Rapids | Michigan | 49503 | — |
| Southfield Oncology Institute, Inc. | Southfield | Michigan | 48076 | — |
| St. Louis Center for Clinical Research | St Louis | Missouri | 63128 | — |
| Nevada Cancer Center | Las Vegas | Nevada | 89109 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| New Mexico Cancer Care Associates | Santa Fe | New Mexico | 87505 | — |
| HemOnCare, P.C. | Brooklyn | New York | 11235 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| SUNY Upstate Medical University | Syracuse | New York | 12310 | — |
| Montefiore Medical Center | The Bronx | New York | 10467-2490 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Ireland Cancer Center | Cleveland | Ohio | 44106 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Hematology Oncology Consultants, Inc. | Columbus | Ohio | 43235 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Palmetto Health | Columbia | South Carolina | 29203 | — |
| Boston Baskin Cancer Group | Memphis | Tennessee | 38104 | — |
| The Boston Baskin Cancer Group | Memphis | Tennessee | 38104 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Cancer Specialists of South Texas, PA | Corpus Christi | Texas | 78412 | — |
| Center for Oncology Research & Treatment | Dallas | Texas | 75230 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Medical College of Wisconsin-FMLH East Neoplastic Diseases and Related Disorders | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00051779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2005 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00051779 live on ClinicalTrials.gov.